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Abstract
Although numerous strategies have been developed to reduce the initial ischemic insult and
cellular injury that occurs during myocardial infarction (MI), few have progressed into the clinical
arena. The epidemiologic and economic impact of MI necessitates the development of innovative
therapies to rapidly and effectively reduce the initial injury and subsequent cardiac dysfunction.
The Eph receptors and their cognate ligands, the ephrins, are the largest family of receptor tyrosine
kinases, and their signaling has been shown to play a diverse role in various cellular processes.
The recent advances in the study of ephrin– Eph signaling have shown promising progress in
many fields of medicine. They have been implicated in the pathophysiology of various cancers
and in the regulation of inflammation and apoptosis. Recent studies have shown that manipulation
of ephrin–Eph cell signaling can favorably influence cardiomyocyte viability and ultimately
preserve cardiac function post-MI. In this article, we explore the hypothesis that manipulation of
ephrin–Eph signaling may potentially be a novel therapeutic target in the treatment of MI through
alteration of the cellular processes that govern injury and wound healing.
Introduction
Cardiovascular disease (CVD) is accountable for nearly 1 in every 3 deaths in the United
States at an annual cost of $149 billion dollars [1,2]. Over the next 20 years, the prevalence
of CVD will increase by 10% with a 3-fold increase in cost [3]. Every year, 980,000
Americans will suffer from a new myocardial infarction (MI) and 470,000 will experience a
recurrent event [1]. Furthermore, MI is associated with an increased risk of heart failure
(HF) [4], and this disease alone is projected to increase by 25% with an 80% increase in cost
by 2030 [3].
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Occlusion due to the embolization of an unstable coronary plaque is the most common cause
of MI [5]. Myocardial necrosis begins within 40 min of coronary occlusion and becomes
transmural within 14 h [6,7]. Structural remodeling of the myocardial architecture in both
the infarcted area and non-infarcted area ensues, leading to progressive ventricular dilation,
dysfunction, and a decline in systolic function that leads to symptoms of HF [7,8]. The
critical time frame during which it is necessary to treat MI to limit functional decline make it
of paramount importance to develop novel therapeutics that can be delivered during the
ischemic event to reduce the acute injury and prevent subsequent cardiac dysfunction.
Current therapies for acute MI are aimed at reducing myocardial oxygen demand and
improving blood flow to nonreperfused myocardium. Percutaneous coronary intervention
and anti-thrombotic therapies have been shown to reduce myocardial injury through
reperfusion of the ischemic myocardium when performed before irreversible cardiomyocyte
(CM) necrosis occurs [9]. Numerous experimental paradigms have shown that reducing
inflammation or promoting angiogenesis in conjunction with grafting cells during the early
stage of injury have reduced adverse remodeling and cardiac dysfunction [10–13].
Granulocyte colony-stimulating factor (G-CSF), the only protein that has progressed to
clinical trials, has been shown to moderately improve cardiac function after MI but the data
remains controversial [14]. Recent evidence also suggests that manipulating the cell
signaling that governs necrosis, apoptosis, and autophagy may enhance CM survival and
ultimately preserve function following MI [15–19]. Although much research has been
conducted to reduce acute ischemic injury, none have yet proven to be clinically beneficial.
Hypothesis
The Eph receptors and their cognate ligands, the ephrins, are the largest family of receptor
tyrosine kinases and have been shown to play diverse roles in differentiation, proliferation,
and migration of various cell types during development [20,21]. These receptors and their
ligands have recently become of noted interest in the study of various cancers and immune
function [22–26]. The role of these receptors and their ligands in the heart is a new and
exciting area of exploration.
Our lab and others have shown that ephrin ligands and their interaction with the Eph
receptors might be beneficial in the treatment of MI [27,28]. Originally known for its
angiogenic properties, we thought ephrinA1-Fc would accelerate revascularization and
thereby improve myocardial infarct healing. However, our published data and others
indicate that this is not the case. By influencing CM survival and possibly regeneration,
some combination of ephrinA1’s stimulation and/or inhibition of EphA receptors may result
in CM protection.
Therefore, we propose that the signaling cascade used by the EphA family of receptor
tyrosine kinases and their cognate ligands can be manipulated as a potential therapeutic
target in the treatment of MI. We will briefly discuss the pathophysiology of MI and what is
currently known about ephrin–Eph signaling in wound healing and the heart to explain our
hypothesis.
Pathophysiology of myocardial infarction
During an ischemic event, CM death progresses from the suben-docardium toward the
epicardium in a transmural manner [6]. Stressed and necrotic cells in the ischemic
myocardium release a host of proteins that recruit inflammatory cells to the area of injury
and T-cells are known to amplify the inflammatory response through production of
cytokines that result in the release of reactive oxygen species (ROS) [29,30]. Within 24 h of
infarction, neutrophils begin to infiltrate from the periphery and macrophages follow within
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72 h. Most neutrophils undergo apoptosis within the first few days but macrophages persist
in the infarcted area, outnumbering neutrophils 2–3 days after the initial insult [31]. In mice,
between 4–7 days, granulation tissue, comprised of inflammatory cells, proliferating
fibroblasts, and endothelial cells, forms by migration of these cells from the border zone into
the infarct area [32]. During this process, a variety of factors are released from macrophages,
including chemokines such as MCP-1, cytokines such as IL-1β and G-CSF, and ROS, such
as nitric oxide and super-oxide anion [33–35]. In addition to the phagocytosis of necrotic
cells, macrophages also are known to influence neovascularization by remodeling the
extracellular matrix to form tunnels which will subsequently be populated by proliferating
and/or migratory vascular cells [36–38]. These molecules, although essential components of
the inflammatory response that aid in the termination of CM damage, also can cause
considerable damage to surrounding viable cells that leads to spreading of the infarct.
The extracellular matrix is constantly remodeled in the normal myocardium to maintain
normal cardiac function through production of interstitial collagen by cardiac fibroblasts.
During infarction, cytokines, MCP-1, and IL-1β recruit myofibroblasts to the region of
injury where, along with fibroblasts, they begin to deposit collagen to form fibrotic scar
tissue [29]. The breakdown of intercellular collagen begins by the loss of homeostasis that
exists between tissue inhibitors of matrix metalloproteinases (TIMPs) and matrix
metalloproteinases (MMPs). The loss of inhibition on MMPs results in the post-translational
cleavage of these proteins that propagates tissue degradation within hours of the infarction
and propagates for days [39,40]. As the matrix disintegrates, myocyte slippage occurs
[41,42]. Necrotic CMs, evidenced by contraction bands and pyknosis, and dead vascular
elements are completely phagocytosed by macrophages within 2 weeks [43,44]. By this
time, the young scar is characterized by the parallel organization of fibroblasts and a
predominance of type I collagen [45]. The extracellular matrix becomes increasingly more
fibrotic and surrounding endothelial cells, fibroblasts, and macrophages undergo apoptosis
[8]. Volume-overload and subsequent hypertrophy of the surviving myocardium ensues with
progressive thinning and stretching of the non-contractile scar tissue. The resultant increase
in ventricular chamber dimensions and myocardial wall stress ultimately leads to inadequate
functional capacity [46].
Ephrin–Eph signaling
Two subclasses of ephrin ligands exist and they are classified by how they are linked to the
plasma membrane. EphrinA ligands are anchored to the cell membrane by a glycosyl-
phosphotidyl-inositol (GPI) linkage while ephrinB ligands are transmembrane-spanning
[47]. Ligands A1–A5 and B1–B3 are typically membrane-bound but a few soluble isoforms
are secreted [48,49].
Cell-to-cell contact or release of the soluble ephrin ligand results in binding to the Eph
receptors, A1–A8, B1–B4, and B6, which leads to dimerization, tetramerization, and/or
clustering of ligands and receptors resulting in the activation or silencing of bidirectional
signaling and consequent activation, or inhibition of intracellular cascades in both cells
[50,51]. This intercellular communication strategy in adhesion and repulsion is a key feature
of their involvement in boundary formation between arteries and veins during blood vessel
development [52].
Direct cell-to-cell interaction of these proteins is required to elicit signaling in the direction
of both the ligand-expressing cell and the receptor-expressing cell. Signaling in both
directions of the contacting cells has been termed bidirectional signaling [53]. It also has
been proposed that the ligand and receptor may be expressed on the surface of the same cell.
Ephrin–Eph cis interaction may actually work to silence bidirectional signaling [47]. More
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recently, EphA and EphB receptors have been shown to interact forming heterotypic clusters
upon ligand binding that results in activation or inhibition depending on the Eph receptor
cell surface expression profile [54].
Of the 5 ephrinA ligands, only ephrinA1 has been shown to bind to all EphA receptors.
EphrinA1 was originally described as a gene product induced by TNF-α to precondition the
vascular endothelial cells to pro-inflammatory cytokines [55]. EphrinA1 also has been
shown to be released as an active soluble monomer to alter molecular signaling to influence
the biology of certain cancers [51]. The function of ephrinA1–EphA activation or silencing
of bidirectional signaling and consequent activation or inhibition of intracellular cascades in
the heart and in response to ischemic injury is a new area of investigation.
To understand the potential role of these proteins in modulating the injury during MI, it is
necessary to examine what is known about ephrin–Eph signaling in inflammation, cell
death, angiogenesis, hypertrophy, and fibrosis.
Ephrin–Eph signaling in wound healing
Inflammation and oxidative stress
Ephrin ligands and Eph receptors are expressed in the vascular endothelium and leukocytes,
and their expression can be enhanced by pro-inflammatory cytokines [56]. Additionally, it
has been shown that activation of EphA2 in vascular endothelial cells induces gene
expression of inflammatory cytokines and recruits inflammatory cells [57]. During the early
stages of inflammation, EphA2 and ephrinB2 expression is localized to the vascular
epithelial and endothelial cells, promoting disruption of the endothelial/ epithelial barrier. As
the inflammatory process progresses, expression of EphA1, A3, B3, and B4 decreases,
permitting infiltrating leukocytes to adhere to endothelial cells by disrupting endothelial/
epithelial barriers [56]. Reorganization of the actin cytoskeleton required for migration of T-
cells, widely recognized for their role in immune surveillance and initiation of the immune
response, may be influenced by ephrinA1–EphA signaling since these cells have been
shown to express EphA1–4, A7, and A8 [58,59]. Mice lacking EphA4 have thymic
hypoplasia and decreased peripheral T-cells, and this was demonstrated to be due to
increased apoptosis and reduced cell cycling [60]. EphrinA1 expression in peripheral T-cells
of asthmatics also has been shown to be reduced and this has been linked to overproduction
of cytokines from increased numbers of activated Th2 cells [61,62]. EphrinA1 stimulation of
T-cells prevents chemotaxis and may be a negative regulator of inflammation [63]. Sharfe et
al. proposed that ephrinA1 enhances integrin-mediated adhesive interactions between T-
cells and endothelial cells while EphA receptor activation of T-cells inhibits it, thus
restricting T-cell transmigration [64]. T-cells have been shown to be involved in the early
recruitment of neutrophils and macrophages in ischemic myocardium [65] as well as in the
later stages of remodeling [66]. Also, inhibition of T-cell accumulation in the infarct zone
during MI has been shown to reduce infarct size [65].
The nature of ephrinA1–EphA interactions in the myocardium remains incomplete. Whether
the ligand and/or receptors are upregulated or downregulated and how their expression
changes over time will most certainly be important in fully understanding the mechanisms of
their action during MI.
Necrosis, apoptosis, and autophagy
The cumulative loss of functioning CMs following MI progresses as an imbrication of
necrotic cell death, apoptosis, and autophagy. Within the first 24 h, extensive loss of CMs is
due to ischemic necrosis [67,68]. Subsequent cell death in the peri-infarct zone is largely
due to apoptosis and occurs in response to distinct cellular signals [69].
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Depaepe et al. observed that EphA7 expression in embryonic cortical progenitors positively
regulates apoptosis to prevent overgrowth by showing that functional deletion of this gene
reduced apoptosis and that ectopic expression of ephrinA5 directly opposed this action [70].
Between 2 and 28 days following experimental induction of spinal cord injury in rats, there
is a dynamic change in EphA7 expression in the acute versus chronic stages of repair,
reflecting the vital role of this receptor in modulating apoptosis to prevent secondary
damage [71]. Also, soluble EphA2-Fc and EphA3-Fc treatment of mice with VEGF-
dependent pancreatic carcinoma resulted in the promotion of endothelial cell apoptosis [72].
Most recently, Jehle et al. [73] observed that increased EphA2 phosphorylation in
immortalized HL-1 cardiomyocytes treated with doxazocin results in apoptosis. Lithocholic
acid administration reduced apoptosis by increasing EphA2-R expression and decreasing
EphA2 phosphorylation [73]. Removal of the ephrinB3 ligand from EphA4 has been shown
to result in caspase-dependent cell death [74] and EphA4-deficient mice have increased
numbers of apoptotic cells, further implicating EphA4 forward signaling in the inhibition of
cellular apoptosis [60]. Additionally, there is evidence that ephrinA reverse signaling can
result in Akt phosphorylation and inhibition of apoptosis [75]. There may be synergistic
effects of ephrinA1 with growth factors such as FGF2 in cells that co-express EphA4 and
FGFRs [76]. It is possible that some combination of changes in the EphA level,
phosphorylation, and signaling may determine the rate of apoptosis of different cell types
following ischemic injury.
The final phase of CM death, which can progress for months, is autophagy. Autophagy is a
process by which, at low levels under normal circumstances in a healthy heart, intracellular
proteins and organelles are removed by lysosomal degradation. This is an important adaptive
feature of terminally differentiated CMs to survive hypoxic conditions by removing
intracellular debris and providing substrates for ATP generation. This also can occur in the
injured myocardium [77,78]. Upregulation of p62 and the ratio of LC3-II/I (microtubule-
associated protein-1 light chain 3-II) are indications of autophagic activation [79]. Beclin-1
and atg7 also are markers of autophagy and beclin-1 is upregulated in response to ischemia
and is inhibited by the anti-apoptotic protein bcl-2 [80]. In addition to enhancing the anti-
apoptotic effects of the bcl-2 protein, it has been shown that the BAG-1 protein can induce
protective autophagy in a rat model of ischemia–reperfusion by linking heat shock proteins
Hsc70/Hsp70 with the proteasome [81]. The role of ephrin–Eph signaling in this process in
the ischemic myocardium has yet to be elucidated.
Angiogenesis
In addition to reducing inflammation, post-infarct revascularization is a critical facet of
myocardial salvage. Sprouting from pre-existing vessels requires that the endothelial cells
dissociate, mobilize, migrate into the ischemic area, proliferate, convene to form tubules,
and recruit mural cells which will stabilize the structure with extracellular matrix deposition
[82]. Studies of the function of the pro-angiogenic ephrinA1 protein and the EphA receptor
family in this process have been largely restricted to models of corneal angiogenesis and
tumorigenesis [83]. A few studies have shown that in endothelial cells, ephrinA1, induced
by TNF-α, IL-1β, and VEGF, can stimulate cell adhesion via αv–β3 integrin and result in
cytoskeletal alterations that inhibit cellular spreading and cause vessel destabilization, a
prerequisite for neovascularization [84,85]. EphA1 expression also has been shown to be
induced by VEGF and TNF-α, and this has been shown to cause endothelial cell migration
and angiogenesis [86]. The loss of EphA2, through anti-sense EphA2 RNA, limits
tumorigenesis in a model of colorectal cancer through inhibition of ephrinA1-induced
expression of VEGF-induced angiogenesis, whereas overexpression of EphA2 in tumor cells
is associated with increased vascular density and ephrinA1 expression is increased in
radioresistant tumors in mice [87,88]. It has been suggested that these paradoxical pro- and
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anti-angiogenic properties attributed to EphA2 during tumor progression are related to Akt-
dependent phosphorylation of EphA2 [89]. More recently, the ligand Slit2 has been shown
to regulate angiogenesis and this process is influenced by the presence or absence of
ephrinA1 [90,91]. This also may be related to the notion that overexpression of EphA2
causes loss of the expression of its ligand [92]. Brantley-Sieders et al. showed that
ephrinA1-stimulated primary bovine and murine pulmonary microvascular endothelial cells
resulted in vascular assembly and migration, whereas, the angiogenic response was blunted
in EphA2-deficient cells [93]. Furthermore, EphA2-deficient mice exhibited hyper-
responsiveness to allergens demonstrated by increased inflammation and defective capillary
growth [94].
EphA2 and EphA4 also have been shown to be expressed on vascular smooth muscle cells
(VSMCs) and there may be crosstalk between endothelial cells and surrounding pericytes
[95,96]. EphA6 and EphA7, expressed on vascular endothelium, are involved in
angiogenesis [97,98]. Ephrin–Eph signaling has been implicated to play a role in
extracellular matrix remodeling [99], however, their role during ischemia is unknown.
Hypertrophy and fibrosis
The process of extracellular matrix remodeling combined with migration, proliferation, and
differentiation of fibroblasts into myofibroblasts that synthesize collagen causes interstitial
and perivascular fibrosis leading to stiffening of the ventricle, vascular dysfunction, and
formation of scar tissue that replaces the necrotic myocardium [100,101]. Additionally,
increased numbers of mast cells in the later phase of wound healing can release proteases
that increase MMP activity and exacerbate the progression of fibrosis and remodeling [102–
104]. Extracellular matrix components, such as fibronectin-EDA, are critical for activating
myofibroblasts and also can negatively impact the inflammatory response and subsequent
remodeling [105]. Molecules, such as HMGB1 which is involved in inflammation, fibrosis,
and CM hypertrophy [106,107], as well as FAK and p38 MAPK, may influence cell motility
and CM hypertrophy [108]. These mediators are downstream targets of pathways that also
can be affected by ephrin–Eph receptor activation. For example, inhibition of cell spreading
and integrin-mediated adhesion resulting from dephosphorylation of FAK occurs in
response to EphA2 stimulation by ephrinA1 [109,110] and FAK-null mouse embryonic
fibroblasts have a defective response to ephrinA1-induced cytoskeletal changes [111]. FAK-
deletion exacerbates apoptosis and infarct size [112] and promotes myofibroblast
differentiation [113]. The pattern of ephrin–Eph expression in CMs and myofibroblasts and
their involvement in matrix remodeling, interstitial fibrosis, hypertrophy, and scar formation
are currently unknown.
Evaluation of the hypothesis: ephrin–Eph signaling as a cardiovascular
therapeutic target
Several studies have investigated the role of ephrin–Eph signaling in the context of
myocardial repair or regeneration after MI. Based on the properties described earlier, it is
reasonable to suggest that these cell surface proteins may promote angiogenesis or reduce
CM death after an ischemic insult through manipulation of other cell processes involved in
wound healing (Fig. 1). We will now discuss the current studies that have explored ephrin–
Eph signaling in the myocardium (Table 1).
The first report was published in 2008 by Mansson-Broberg and colleagues [114]. The
authors induced MI in mice through permanent coronary artery occlusion and then assessed
mRNA levels of the EphB4 receptor and the ephrinB2 ligand in CMs 2 weeks post-MI. At
each time point examined, they found the ligand and receptor were inversely expressed. The
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ephrinB2 chimeric protein, ephrinB2-Fc, also induced endothelial cell proliferation and
sprouting when used in vitro. Following MI, mice that were treated with an injection of
ephrinB2-Fc had a 28% increase in capillary density in the peri-infarct region, and a trend
towards increased mitotic activity. However, the authors did not comment on the reduction
of infarct size or echocardiographic function. These data do suggest that a single, systemic
dose of ephrinB2-Fc is sufficient to activate the EphB4 receptor and this may promote
angiogenesis, although the extent of cardioprotection has not been determined.
Our group recently published the gene expression pattern of EphA receptors and the
ephrinA1 ligand in the healthy murine myocardium and in response to nonreperfused MI
[27,115]. Expression of the ephrinA1 protein was seen in CMs throughout the myocardium
and expression increased post-MI. To test the therapeutic role of this system the ephrinA1-
Fc chimera was injected directly into the myocardium of mice immediately following
permanent coronary occlusion. This resulted in a significant modulation of mRNA
expression of several Eph receptors, suggesting that beneficial changes in ligand-receptor
binding had occurred. Expression of EphA1–A3 and EphA7 were significantly increased
following MI while EphA6 expression decreased. Treatment with ephrinA1-Fc further
increased EphA1 and EphA2 gene expression and resulted in a 2-fold increase in EphA4.
Importantly, infarct size was significantly reduced, along with inflammatory cell infiltration
and cardiac troponin I release. Treatment with ephrinA1-Fc also increased phosphorylated
Akt protein expression, reduced PARP cleavage, and increased BAG-1 expression,
indicative of improved cellular survival via reduction in apoptosis and possibly enhanced
autophagy. These data represent a cardioprotective role for exogenous ephrinA1-Fc
administration in the setting of acute MI and may present a novel therapeutic approach to be
used alone or in conjunction with stem/progenitor cells or other biomaterials. Additionally,
Frieden et al. generated ephrinA1-null mice in which they observed defective valve
morphogenesis during development and reduced ejection fraction and fractional shortening
in adult mice, not due to changes in blood pressure, but rather due to intrinsic cardiac
dysfunction [116]. Collaborative studies are in progress to further explore the adult cardiac
phenotype and response to acute and chronic injury.
Subsequently, Goichberg et al. investigated the role of ephrinA1 in myocardial repair [28].
In agreement with our findings, they observed ephrinA1 protein expression on CMs.
Furthermore, they showed that treatment of human cardiac stem cells (hCSCs) in vitro
resulted in increased cellular motility, as well as in vivo following MI. Infarct size was
reduced by 37% and the volume of the myocardium increased 2-fold with ephrinA1-
activated hCSCs compared to control hCSCs. Treatment with ephrinA1-activated hCSCs
ultimately increased ventricular pressure and ejection fraction after MI compared to controls
[28], although the relative contribution of cardiac stem cells to CM regeneration versus
neoangiogenesis remains unclear. Again, these data implicate a critical role for ephrinA1
signaling in the context of myocardial repair and present a new and exciting area in the
development of therapies to repair the myocardium after MI.
Genet et al. have described a role of ephrinB1 in the murine heart [117]. Although this study
did not include an experimental model of MI, their characterization of the expression of
ephrinB1 in the murine heart provides further evidence for the role of ephrinB1 in CM
stability. EphrinB1-deficient mice were shown to have a more disorganized CM structure
and extracellular matrix compared to control mice. Claudin-5, a protein involved in CM
stability, was noted to be decreased in mice deficient of ephrinB1 and cardiac sarcomere
disorganization was noted by electron microscopy. EphrinB1-deficient mice also were
observed to have more dilation of the left ventricle during diastole, decreased
atrioventricular conduction evidenced by lengthening of the PR interval, and had a poorer
survival with ascending aortic banding and subsequent pressure overload than controls.
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These results highlight the pivotal role for ephrinB1 in cardiac tissue and its capacity to
preserve cardiac function during times of stress.
Consequences of the hypothesis and conclusions
Although numerous therapies have been and are currently being investigated to treat MI,
very few have shown any promise to be clinically applicable. The economic impact of MI
on our healthcare system necessitates the development of novel therapeutics to reduce the
initial injury and blunt the progressive cardiac dysfunction. The current standard of care
revolves around the implementation of early reperfusion of the ischemic myocardium within
a critical time period to preserve CM viability while neglecting any aspect that could alter
the biological basis for the injury observed during and after infarction.
The recent advances in the study of ephrin–Eph signaling have shown promising progress in
many fields of medicine. Ephrin–Eph signaling has been shown to regulate inflammation
and apoptosis in other tissues and also possibly reduce the extent of these injurious
processes during the early phases of the ischemic insult. Although there are no reports that
show their signaling directly enhances autophagy during MI, we hypothesize that their
activation will be beneficial during ischemia. Ephrin–Eph signaling also has been reported
to be pro-angiogenic and many of the downstream targets of its signaling pathway could
negatively influence the effects of hypertrophy and fibrosis during wound healing. Once a
more detailed understanding of ephrin–Eph signaling during ischemia is uncovered, we will
then be able to evaluate the potential impact of this signaling pathway in the treatment of
MI.
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Potential/hypothetical pathways modified by EphrinA1-EphA signaling. EphrinA1
potentially mediates cardioprotection during myocardial infarction by increasing
phosphorylated-Akt to decrease apoptosis through upregulating bcl-2 and decreases the
inflammatory response through the downregulation of NF-κB. The possible promotion of
autophagy is mediated through the downregulation of mTOR and subsequent increase in
AMPK.
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Table 1
Ephrin–Eph signaling in myocardium.
Study Ephrin–Eph signaling Model Results
Mansson-Broberg et al. [114] EphB4, EphrinB2 Nonreperfused coronary ligation EphrinB2 role in angiogenesis
Dries et al. [27] EphA Family, EphrinA1 Nonreperfused coronary ligation EphrinA1 role in myocardial protection
Goichberg et al. [28] EphrinA1 Human cardiac stem cells EphrinA1 role in myocardial protection
Genet et al. [117] EphrinB1 Isolated CM studies EphrinB1 role in CM structure stability
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